Revolutionizing Glioblastoma Treatment with AI at the University of Virginia School of Medicine
Glioblastoma is an exceptionally aggressive and malignant form of brain tumor that arises from glial cells, particularly astrocytes, within the brain or spinal cord. This neoplasm is characterized by its rapid growth and invasive nature, posing significant challenges for treatment and patient prognosis.
Exciting advancements are underway at the University of Virginia School of Medicine, where scientists are harnessing the transformative power of artificial intelligence to enhance and expedite treatment for glioblastoma, the most aggressive form of brain cancer.
Led by UVA researcher Dr. Bijoy Kundu, a team of dedicated scientists is pioneering an innovative AI imaging technique designed to differentiate between tumor progression and the brain changes induced by treatment. Traditionally, this critical distinction could take months to establish, leaving physicians in a state of uncertainty regarding tumor growth and delaying vital treatment decisions.
In initial tests, Dr. Kundu’s AI approach has already surpassed the standard clinical methods, achieving an impressive accuracy rate of 74% when evaluated on 26 glioblastoma patients immediately following treatment.
“Our objective is to train the AI on additional patient data to boost this accuracy to over 80% for clinical application,” stated Dr. Kundu, who is affiliated with the UVA Cancer Center, the Department of Radiology and Medical Imaging, and the Department of Biomedical Engineering.
This breakthrough could have profound implications for patient care. “Early differentiation between tumor recurrence and treatment effects would allow for timely adjustments in therapy for brain cancer patients,” explained Dr. David Schiff, a key member of UVA’s Departments of Neurology, Neurosurgery, and Medicine, and co-director of UVA Health’s Neuro-Oncology Center.
Transforming Glioblastoma Care
Glioblastoma accounts for more than half of all primary brain tumors and is notorious for its rapid growth and aggressive nature, with a typical survival time of only 15 months post-diagnosis. This urgency underscores the necessity for swift action by healthcare providers, as timely interventions can significantly extend survival and enhance patients’ quality of life.
Currently, physicians must wait three to four months after treatment to evaluate tumor progression, relying on magnetic resonance imaging (MRI) or, in some cases, invasive brain surgery.
